DRL-Header DRL-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): Cannabinol

            Therapeutic Area: Genetic Disease Product Name: INM-755

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 16, 2021

            Details:

            InMed intends to use the net proceeds from the offering for working capital purposes which also includes development of their INM-755 program.